Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells

Cancer Letters

Volumn 313, Issue 1, 2011, Pages 54-63

  Zhao, Yong ^a   Wang, Zhishan ^a   Jiang, Yiguo ^b   Yang, Chengfeng ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Akt; HER2; IGF IR; PTEN; Rac1; Trastuzumab resistance

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TIAM1; RAC1 PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN SKBR3; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINOQUINOLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE;

EID: 80054109336     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.023     Document Type: Article

References (37)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
3. Vogel C., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. A preliminary report. Eur. J. Cancer 2001, 37(Suppl. 1):25-29.
4. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
5. Seidman A.D. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. Nat. Clin. Pract. Oncol. 2006, 3:178-179.
6. Seidman A.D., Berry D., Cirrincione C., Harris L., Muss H., Marcom P.K., Gipson G., Burstein H., Lake D., Shapiro C.L., Ungaro P., Norton L., Winer E., Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 2008, 26:1642-1649.
7. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. New Engl. J. Med. 2007, 357:39-51.
8. Nahta R., Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
9. Garrett J.T., Arteaga C.L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 2011, 11:793-800.
10. Yang C., Liu Y., Lemmon M.A., Kazanietz M.G. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol. Cell. Biol. 2006, 26:831-842.
11. Kim J.S., Peng X., De P.K., Geahlen R.L., Durden D.L. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood 2002, 99:694-697.
12. Ferraro D., Corso S., Fasano E., Panieri E., Santangelo R., Borrello S., Giordano S., Pani G., Galeotti T. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 2006, 25:3689-3698.
13. Fiedler L.R., Schonherr E., Waddington R., Niland S., Seidler D.G., Aeschlimann D., Eble J.A. Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of alpha2beta1 integrin activity. J. Biol. Chem. 2008, 283:17406-17415.
14. Burridge K., Wennerberg K. Rho and Rac take center stage. Cell 2004, 116:167-179.
15. Vega F.M., Ridley A.J. Rho GTPases in cancer cell biology. FEBS Lett. 2008, 582:2093-2101.
16. Rossman K.L., Der C.J., Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 2005, 6:167-180.
17. Schiller M.R. Coupling receptor tyrosine kinases to Rho GTPases-GEFs what's the link. Cell. Signal. 2006, 18:1834-1843.
18. Fritz G., Just I., Kaina B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer 1999, 81:682-687.
19. Schnelzer A., Prechtel D., Knaus U., Dehne K., Gerhard M., Graeff H., Harbeck N., Schmitt M., Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000, 19:3013-3020.
20. Yang C., Klein E.A., Assoian R.K., Kazanietz M.G. Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Biochem. J. 2008, 410:167-175.
21. Yang C., Liu Y., Leskow F.C., Weaver V.M., Kazanietz M.G. Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin. J. Biol. Chem. 2005, 280:24363-24370.
22. Baugher P.J., Krishnamoorthy L., Price J.E., Dharmawardhane S.F. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res. 2005, 7:R965-R974.
23. Sosa M.S., Lopez-Haber C., Yang C., Wang H., Lemmon M.A., Busillo J.M., Luo J., Benovic J.L., Klein-Szanto A., Yagi H., Gutkind J.S., Parsons R.E., Kazanietz M.G. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol. Cell 2010, 40:877-892.
24. Wang Z., Zhao Y., Smith E., Goodall G.J., Drew P.A., Brabletz T., Yang C. Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by micoRNA-200b. Toxicol. Sci. 2011, 12:110-122.
25. Gao Y., Dickerson J.B., Guo F., Zheng J., Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. USA 2004, 101:7618-7623.
26. Cai D., Iyer A., Felekkis K.N., Near R.I., Luo Z., Chernoff J., Albanese C., Pestell R.G., Lerner A. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res. 2003, 63:6802-6808.
27. van der Heijden M.S., Bernards R. Inhibition of the PI3K pathway: hope we can believe in?. Clin. Cancer Res. 2010, 16:3094-3099.
28. Dokmanovic M., Hirsch D.S., Shen Y., Wu W.J. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol. Cancer Ther. 2009, 8:1557-1569.
29. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., Sahin A.A., Esteva F.J., Hortobagyi G.N., Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 2011, 17:461-469.
30. Zheng Y. Dbl family guanine nucleotide exchange factors. Trends Biochem. Sci. 2001, 26:724-732.
31. Thomas E.K., Cancelas J.A., Chae H.D., Cox A.D., Keller P.J., Perrotti D., Neviani P., Druker B.J., Setchell K.D., Zheng Y., Harris C.E., Williams D.A. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007, 12:467-478.
32. Lee T.K., Man K., Ho J.W., Wang X.H., Poon R.T., Sun C.K., Ng K.T., Ng I.O., Xu R., Fan S.T. Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis 2005, 26:681-687.
33. Walker K., Olson M.F. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 2005, 15:62-68.
34. Fritz G., Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr. Cancer Drug Targets 2006, 6:1-14.
35. Nassar N., Cancelas J., Zheng J., Williams D.A., Zheng Y. Structure-function based design of small molecule inhibitors targeting Rho family GTPases. Curr. Top. Med. Chem. 2006, 6:1109-1116.
36. Onesto C., Shutes A., Picard V., Schweighoffer F., Der C.J. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol. 1864, 439(2008):111-129.
37. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Update 2008, 11:32-50.